Year None202420232022202120202019201820172016 June 27, 2024 Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights Go to June 26, 2024 Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe Go to June 3, 2024 Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting Go to May 31, 2024 Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum Go to May 22, 2024 Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum Go to May 13, 2024 Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting Go to Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »
June 27, 2024 Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights Go to
June 26, 2024 Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe Go to
June 3, 2024 Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting Go to
May 31, 2024 Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum Go to
May 22, 2024 Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum Go to